PARP inhibitors: its role in treatment of cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Poly(ADP-ribose) polymerase (PARP) is crucial for DNA repair, especially base excision repair (BER) of single-strand breaks (SSBs).
• Impaired BER leads to SSBs accumulating and becoming double-strand breaks (DSBs), increasing reliance on homologous recombination (HR) and nonhomologous end joining repair pathways.
• BRCA-deficient cells, with defective HR, are particularly vulnerable to BER pathway impairment.

Purpose of the Study:

• To review clinical trial results evaluating PARP inhibitors based on two key principles.
• To assess the efficacy of PARP inhibitors as single agents and in combination with chemotherapy.
• To explore future directions in PARP inhibitor development.

Main Methods:

• Review of current clinical trial data on PARP inhibitors.
• Analysis of PARP inhibitor activity in BRCA-mutated cancers.
• Evaluation of PARP inhibitors in combination with DNA-damaging chemotherapies.

Main Results:

• PARP inhibitors preferentially kill cancer cells with BRCA mutations.
• PARP inhibitors enhance chemotherapy cytotoxicity by inhibiting DNA repair.
• Clinical trials show significant activity in BRCA1/2-associated ovarian and breast cancers, and triple-negative breast cancer.

Conclusions:

• PARP inhibitors represent a promising targeted therapy for specific cancer types, particularly those with HR deficiencies.
• The combination of PARP inhibitors with chemotherapy warrants further investigation.
• Continued research into PARP inhibitor development holds potential for advancing cancer treatment.